Brief: Eiger To Discontinue Phase 3 Limt-2 Trial Of Peginterferon Lambda In Patients With Chronic Hepatitis Delta

Eiger Biopharmaceuticals

12/09/2023 22:30

Eiger BioPharmaceuticals Inc  EIGR.O :
    * EIGER BIOPHARMACEUTICALS INC - EIGER TO DISCONTINUE PHASE
3
LIMT-2 TRIAL OF PEGINTERFERON LAMBDA IN PATIENTS WITH CHRONIC
HEPATITIS DELTA
    * EIGER TO DISCONTINUE PHASE 3 LIMT-2 TRIAL OF PEGINTERFERON
LAMBDA IN PATIENTS WITH CHRONIC HEPATITIS DELTA
    * EIGER BIOPHARMACEUTICALS : TO WORK CLOSELY WITH FDA AND
OUR
INVESTIGATORS TO CONDUCT AN ORDERLY TERMINATION OF LIMT-2 STUDY
IN INTEREST OF PATIENT SAFETY
    * EIGER BIOPHARMACEUTICALS INC - WE CONTINUE TO EVALUATE
STRATEGIC
PARTNERING OPTIONS FOR OUR VIROLOGY ASSETS
    * EIGER BIOPHARMACEUTICALS INC - IS NO LONGER IN ACTIVE
DISCUSSIONS WITH POTENTIAL PARTNERS FOR A WORLDWIDE LICENSE FOR
PEGINTERFERON LAMBDA

Source text for Eikon:  ID:nPnbF34cJa 
Further company coverage:  EIGR.O